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Abstract
Tuberculosis is still a leading cause of death worldwide. The selection and spread of Mycobacterium tuberculosis multidrugresistant (MDR-TB) and extensively drug-resistant strains (XDR-TB) is a severe public health problem. Recently, two different
classes of chemical series, the benzothiazinones (BTZ) and the dinitrobenzamide (DNB) derivatives have been found to be
highly active against M. tuberculosis, including XDR-TB strains. The target of BTZs is DprE1 protein which works in concert
with DprE2 to form the heteromeric decaprenylphosphoryl-b-D-ribose 29-epimerase, involved in Decaprenyl-PhosphoArabinose (DPA) biosynthesis. Interestingly, it has been shown that the DNBs block the same pathway thus suggesting that
both drugs could share the same target. Moreover, in Mycobacterium smegmatis the overexpression of the NfnB
nitroreductase led to the inactivation of the BTZs by reduction of a critical nitro-group to an amino-group. In this work
several spontaneous M. smegmatis mutants resistant to DNBs were isolated. Sixteen mutants, showing high levels of DNB
resistance, exhibited a mutation in the Cys394 of DprE1. Using fluorescence titration and mass spectrometry it has been
possible to monitor the binding between DprE1 and DNBs, achieving direct evidence that MSMEG_6382 is the cellular
target of DNBs in mycobacteria. Additionally, M. smegmatis mutants having low levels of resistance to DNBs harbor various
mutations in MSMEG_6503 gene encoding the transcriptional repressor of the nitroreductase NfnB. By LC/MS2 analysis it has
been demonstrated that NfnB is responsible for DNB inactivation. Taken together, our data demonstrate that both DNB and
BTZ drugs share common resistance mechanisms in M. smegmatis.
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stages of preclinical and early clinical evaluations [6]. Moxifloxacin and gatifloxacin are currently in phase three of clinical trials,
while PA-824 and TMC207 are in phase two and SQ109,
AZD5847, and linezolid in phase one [7].
Recently, new and effective antitubercular drugs, belonging to
the class of benzothiazinones (BTZs), have been found to be highly
active against M. tuberculosis resistant and sensitive strains,
including MDR and XDR strains. It has been demonstrated that
BTZs rapidly kill M. tuberculosis in vitro, ex vivo, and in vivo [8].
The cellular target of BTZs in M. tuberculosis is the enzyme
DprE1 which is part of the decaprenylphosphoryl-b-D-ribose 29epimerase together with DprE2. DprE1 is encoded by the dprE1
gene, also named Rv3790 [8]. DprE1 and DprE2 are involved in
the conversion of decaprenylphosphoryl-D-ribose (DPR) to

Introduction
Tuberculosis, an infectious disease caused by Mycobacterium
tuberculosis, is still a leading cause of death in developing countries
and a resurgent disease in developed countries [1]. The selection
and increasing spread of M. tuberculosis multidrug-resistant (MDRTB), extensively drug-resistant (XDR-TB) and, more recently,
totally drug-resistant (TDR) or super-XDR strains is a serious
threat to public health, in particular to immunocompromised
patients [2–5].
For these reasons, there is an urgent need of new drugs for
tuberculosis treatment with novel mechanisms of action and a
necessity to identify new drug targets [4]. A major international
effort has created a pipeline of new drug candidates at various
PLoS ONE | www.plosone.org
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of the synthesis of decaprenylphosphoryl-D-arabinose [15],
suggesting that DprE1 could be the cellular target not only of
BTZ, but also of DNB drugs.
The most active compounds among DNBs exhibit a nitro group
at positions 3 and 5 in the benzene moiety. The two major
compounds from this series, [N-(2-(4-methoxyphenoxy) ethyl)-3,5dinitrobenzamide] and [N-(2-(benzyloxy) ethyl)-3,5-dinitrobenzamide], named DNB1 and DNB2 respectively, are also highly
active against M. tuberculosis MDR and XDR strains [15].
In order to understand if DNBs can be suitable candidates for
the antitubercular therapy, one of the main points is to know the
mechanism by which they fulfill their activity at the cellular level.
To this purpose, through microbiological, genetic and biochemical
approaches, we investigated the molecular bases of the resistance
to DNBs in M. smegmatis. According to two different levels of
resistance, two different mechanisms were found which paralleled
those exhibited by BTZ compounds.

decaprenylphosphoryl-D-arabinose (DPA), which is the only araf
donor for arabinogalactan and lipoarabinomannan synthesis in the
mycobacterial cell wall [9–11].
Moreover recently Crellin and collaborators (2011) demonstrated the essentiality of M. smegmatis dprE1 (or MSMEG_6382) [12].
This result, combined with the conservation of dprE1 in all
sequenced mycobacterial genomes, suggests that decaprenylphosphoryl arabinose synthesis is essential in all mycobacteria [12].
It was shown that BTZs specifically react with the cysteine
residue at position 387 in the DprE1 active site leading to the
formation of a covalent complex between BTZs and DprE1 [13].
Additionally, in all the M. tuberculosis BTZ resistant mutants
found to date, Cys387 of DprE1 was replaced by serine or glycine
unravelling the key role played by Cys387 in BTZ bactericidal
activity. The cysteine is a highly conserved amino acid residue also
in orthologous enzymes from various Actinobacteria and its
replacement by alanine and serine in Mycobacterium avium and
Mycobacterium aurum, respectively, is the cause of their natural
resistance to BTZ [8].
The benzothiazinone BTZ043, which contains a nitro-group in
its molecule, is a very effective agent against mycobacteria; on the
other hand, the corresponding amino-derivative, found in the blood
and urine of treated animals, is significantly less active in inhibiting
both M. tuberculosis and Mycobacterium smegmatis growths [8]. The
reduction of the critical nitro group into an amino group has been
reported in M. smegmatis mutants resistant to BTZ, overexpressing
the nitroreductase NfnB [14]. The crystal structure of NfnB in
complex with its essential cofactor flavin mononucleotide shows
that an amino acid stretch which is likely to be essential for the
interaction with BTZ is also contained into DprE1 enzyme. No
nfnB ortholog could be found in M. tuberculosis genome and until
now the pathogen seems to lack nitroreductases able to carry out
BTZ inactivation [14].
Another new class of potent antitubercular drugs is represented
by the dinitrobenzamide derivatives (DNBs),whose activity was
identified through an ex vivo screening of chemicals which interfere
with M. tuberculosis replication within macrophages [15,16].
Incubation of M. tuberculosis with DNBs resulted in the inhibition

Materials and Methods
Bacterial strains and growth conditions
All cloning steps were performed in Escherichia coli XL1-Blue,
following standard methods [17]. The oligonucleotides used for all
PCR amplifications are shown in Table 1.
For expression studies, the strain utilized was E. coli BL21(DE3),
which was grown either in Luria-Bertani (LB) broth or on LB agar.
M. smegmatis strains were grown aerobically at 37uC with orbital
shaking at 200 rpm either in Middlebrook 7H9 medium (Becton
Dickinson) or on Middlebrok 7H11 agar (Becton Dickinson), both
supplemented with 10% OADC Middlebrook Enrichment.
For E. coli cultures, when necessary, antibiotics were added at
the following concentrations: ampicillin,100 mg/ml; chloramphenicol, 34 mg/ml; and kanamycin, 50 mg/ml; both DNB and BTZ
were dissolved in dimethyl sulfoxide (DMSO).

M. smegmatis resistant mutants
The isolation of M. smegmatis mutants was performed by plating
,1010 cells from an exponential growth phase wild-type culture

Table 1. Oligonucleotides used in this work.

Oligonucleotides

Sequence (59-39)

Purpose

OXRE1

GATGTCGCTCAGTTGCACC

Sequencing of MSMEG_6382 gene

OXRE2

ACCTGTTCTGGGCGACCGT

OXRE3

GTGTAGTTCGCCTCGCTGC

OXRE4

AGGCTACTGCTTTTCTGGA

3791smF

CAAGGTGATGGACGCCGAC

3791smR

CGCGTGCAGCTGGTTGGAC

AL52tetFOR

CCGCGCCGCTGACCACCTCG

AL52tetREV

CATCGGCTACGTCTTCGCGCAC

NfnBfor

TATCTAGACGGGCAGGCACATCG

NfnBrev

CGGGATCCTAACGGGTCAGCGG

nfnBinF

GGCCAGGTCGACAGTGGGC

nfnBinR

GGCGGCCGCGGCGACGAT

mysAF

CGTCGCCGATGGTCTG

mysAR

CCACGCCCGAAGAGC

nfnBF

GCGGTTCTACGGTGCCCC

nfnBR

CGGTCATCGCGAGCATCAG

Sequencing of MSMEG_6385 gene

Sequencing of MSMEG_6503 gene

Sequencing of nfnB gene

Amplification of MSMEG_6503-nfnB intergenic region

Real-Time PCR

doi:10.1371/journal.pone.0026675.t001
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subsequently at 17uC O/N. Bacterial cells were then collected by
centrifugation, resuspended in lysis buffer (50 mM NaH2PO4,
300 mM NaCl, and 10 mM imidazole, pH 8.0) supplemented
with protease inhibitor cocktail (Sigma), sonicated at 800 W for 6
minutes, cleared by ultracentrifugation, and the supernatant was
applied to a HisTrap HP column (GE-Healthcare) equilibrated in
the same buffer. Proteins were eluted with scalar concentrations
(20 to 500 mM) of imidazole, and fractions containing the DprE1
protein, as detected by 10% SDS-PAGE, were collected, dialyzed
O/N at 4uC against 50 mM Tris, 150 mM NaCl, 1 mM EDTA
and 1 mM DTT, pH 7.0, and incubated for 12 hours at 4uC in
the presence of 10 units of PreScission Protease (GE Healthcare).
The digested protein was finally concentrated and applied to a
HiLoad 16/60 Superdex-200 column (GE-Healthcare) equilibrated in 50 mM potassium phosphate pH 8.0, 100 mM KCl. The
enzyme was eluted by the same buffer and fractions containing
DprE1 were pooled.

onto 7H11 medium containing different concentrations of N-(2-(3chlorobenzyloxy)ethyl)-3,5-dinitrobenzamide (DNB3), ranging
from 8 to 300-fold the Minimal Inhibitory Concentration (MIC)
for the wild-type strain. DNB3 was chosen over DNB1 and DNB2
because of its increased solubility in agar medium. Plates were
incubated at 37uC for 10 days. The phenotype of the resistant
colonies hereafter referred as DNBR-High and DNBR-Low was
confirmed by determining the MIC of DNB3; the experiment was
repeated three times. AL49, AL55 and GM22 mutants, that had
been selected for their resistance to BTZs, had previously been
reported [14].

MIC determinations
A single colony of each mycobacterial strain was inoculated in
complete Middlebrook 7H9. Cell cultures were grown at 37uC
until exponential growth phase (,108 CFU/ml) was reached.
After dilution to the final concentration of about 106 CFU/ml,
1 ml of cell cultures was streaked onto plates containing two-fold
serial dilutions of appropriate compounds. MIC values were
assigned as the lowest drug concentrations inhibiting bacterial
growth. All experiments were repeated three times.

Fluorescence titrations
Steady state fluorescence titration of DprE1 was performed
using 2–6 mM of protein, in 20 mM potassium phosphate buffer,
pH 7.5, in the presence of different concentrations of DNB1 or
DNB3 (from 0 to 256 mM). Measurements were performed at
25uC with a Jasco FP-6500 spectrofluorimeter (Jasco Europe,
Cremalla, Italy). The excitation wavelength was 450 nm (3 nm slit
width) and the emission was recorded between 470 and 600 nm
(10 nm slit width). Spectra were corrected for the blanks,
performed in the same conditions, but in the absence of protein.
All experiments were performed at least in duplicate. The
dissociation constants (Kd) were calculated using the following
equation (1), with the Sigma Plot 7.0 software (SPSS Inc):

DNA sequencing of MSMEG_6382, MSMEG_6385,
MSMEG_6503, and nfnB genes from M. smegmatis
isolated mutants
MSMEG_6382, MSMEG_6385, MSMEG_6503, and nfnB genes
were amplified by PCR, using primers reported in Table 1 and
PFU Taq DNA polymerase (Promega), according to the manufacturer’s instructions. The bacterial lysates from M. smegmatis
mutants were used as templates. The PCR products were purified
using the Wizard SV Gel and PCR clean-up system (Promega) and
directly sequenced.

F ~F0 zFmax

Real Time PCR analysis
RNA was isolated from M. smegmatis wild-type and mutant
strains by using RNeasy Mini Kit (Qiagen). After DNase treatment
(Ambion), all samples were tested by conventional PCR to
eliminate DNA contamination. 1 mg of total RNA was reversetranscribed with Quantitect reverse transcription kit (Qiagen),
according to the manufacturer’s instructions. Samples corresponding to 50 ng of RNA were used in each PCR reaction in a final
volume of 15 ml. Quantitative PCR were performed using
QuantiTect SYBR Green PCR Master Mix (Qiagen) on a Rotor
Gene 6000 (Corbett Life Science). The primer pairs used were as
follows: mysAF and mysAR for mysA; nfnBF and nfnBR for nfnB
(Table 1). mysA (MSMEG_2758), coding for sA factor, was used as
an internal invariant control for the normalization of nfnB
expression levels. Expression data were calculated with the -2DDCt
method (DCt = Ct sample – Ct control) and were reported as -fold
change in gene expression of the sample (mutant strain)
normalized to the invariant gene (mysA) relative to the control
wild-type strain.

2½E

ð1Þ

where F is the observed fluorescence intensity, [E] is the enzyme
concentration, [L] is the ligand concentration, F0 and Fmax are the
fluorescence intensity at [L] = 0 and the total change in
fluorescence intensity, respectively, and Kd is the fitted dissociation constant.

LC/MS2 analysis of DNB metabolized by NfnB
5 mg of NfnB protein expressed and purified as previously
described [14] were incubated in 50 mM MOPS, pH = 7.9, 5 mM
2-mercaptoethanol, 10 mM MgCl2 buffer, and 80 mM NADPH.
After addition of DNB1 at a final concentration of 7 mM, the
reaction was carried out for 30 min at 37uC (each experiment was
also performed in the absence of either NfnB or NADPH).
The presence of a hydroxyl amine and of nitro reduced forms of the
drugs were analysed by LC/MS/MS. Each experiment was
performed in triplicate. The data shown are the mean value
obtained.
Chromatographic separation was performed using a Waters
Acquity Ultra Performance LC system (Waters, milford, MA,
USA) equipped with an Acquity UPLCTM BEH C18 column
(100 mm 6 2.1 mm, i.d., 1.7 mm particle size, Waters, Milford,
MA, USA). A linear gradient at a flow rate of 0.3 ml/min was
used for the elution. Mobile phases were: A; 0.1% formic acid and
B; acetonitrile containing 0.1% formic acid. Gradient condition
was: 0–4 min, 20-90% B in A (linear); 4–5 min, 90% B in A
(isocratic); 5–6 min, 90-20% B in A (linear); 6–7 min, 20% B in A
(isocratic). The separated compounds were detected by a Waters
Micromass Quattro Premier XE tandem quadrupole mass

Cloning, expression and purification of recombinant
DprE1 from M. smegmatis (MSMEG_6382)
The MSMEG_6382 gene, encoding DprE1 in M. smegmatis, was
cloned into HindIII/pET-32b vector (Novagen), to obtain the
corresponding protein fused to six histidine residues and
thioredoxin protein at its N-terminus. Briefly, E. coli BL21(DE3)pLysS cells transformed with MSMEG_6382/pET-32b construct
were grown onto LB agar containing ampicillin (100 mg/ml).
Roughly 100 colonies were inoculated in ZYP-5052 auto-inducing
medium supplemented with ampicillin at 37uC for three hours and
PLoS ONE | www.plosone.org
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spectrometer (Waters, Manchester, UK). The instrument was
operated using [M+H]+1 and [M-H]-1 ionization modes. The
following method parameters were used for the DNB1, DNB1NH2, and DNB1-NHOH analysis; ion source temperature,
100uC; desolvation temperature, 300uC; desolvation gas flow,
750 L/h (nitrogen); Cone gas flow, 100 L/h (nitrogen); capillary
voltage, 5 kV. 2 0V cone voltage and 20eV collision energy were
used for [M+H]+1 mode and 30V cone voltage and 20eV collision
energy were used for [M-H]-1 mode, respectively and argon was
used as collision gas at a pressure of 3.061023 mbar.

($1000 X MIC) (Table 2); the second series of mutants presented
a lower level of resistance to DNB (64-128 X MIC) and to BTZ
(16-64 X MIC) (Table 3). The M. smegmatis mutants GM22, AL49
and AL55, characterized by a low level of resistance to BTZ043
[14], were also resistant to DNB (256 X MIC) (Table 3).
DNBs have been reported to inhibit DPA biosynthesis [15].
Therefore, all the DNB resistant mutants were screened for the
presence of mutations in MSMEG_6382 gene (ortholog of M.
tuberculosis Rv3790), which codes for DprE1, a component of the
heteromeric decaprenylphosphoryl-b-D-ribose 29-epimerase.
MSMEG_6382 gene was amplified by PCR and sequenced from
genomic DNA of all M. smegmatis mutants.
All the M. smegmatis mutants with a higher level of resistance to
DNB (DNBR-High) (and also to BTZ) had a point mutation at
codon 394 of MSMEG_6382 gene, as previously observed for M.
smegmatis mutants resistant to BTZ [8]. This position (Cys394)
corresponds to Cys387 position in M. tuberculosis Rv3790 gene. All
mutants turned out to have the substitution Cys394Gly in DprE1,
but DNBR-High4 showed a serine instead of cysteine at the same
position and higher BTZ resistance than the other ones (.4000 X
MIC) (Table 2). These data support the idea that Cys394 is
involved in the binding of DNB, as previously suggested for BTZ
[8].
Taken together, these results give clear evidence that
MSMEG_6382 is a target of DNB drugs and target modification
confers a high level of resistance to these compounds.
In opposition to the aforementioned strains, mutants less
resistant to DNB and to BTZ (DNBR-Low1-3,Table 3) did not
show mutations in MSMEG_6382 gene, thus suggesting that their
resistance should be accomplished by a different molecular
mechanism.
MSMEG_6385 gene (ortholog of M. tuberculosis Rv3791 or dprE2)
encodes the second component (DprE2) of the heteromeric
decaprenylphosphoryl-b-D-ribose 29-epimerase [10]. Given that
a possible mutation in this gene could affect the binding of the
drugs to DprE1, thus causing resistance, MSMEG_6385 gene of
mutants DNBR-Low1-3 (Table 3) was sequenced. No mutations
were found, excluding the involvement of DprE2 in the
mechanism of DNB resistance.
Recently, a new mechanism of BTZ resistance was described
[14] for a few M. smegmatis mutants (GM22, AL49 and AL55;
Table 3) where the nitroreductase NfnB overexpression is
responsible for BTZ inactivation because of a mutation in
MSMEG_6503 gene coding for nfnB transcriptional repressor
[14]. Thus, in order to identify the gene(s) responsible for the
resistance phenotype in these DNB resistant mutants, nfnB and
MSMEG_6503 genes were amplified and sequenced. No one
mutant had a mutation in nfnB gene, but all the mutants DNBRLow
showed a mutation, although different from each other, in
MSMEG_6503 regulatory gene (Table 3).
DNBR-Low1 mutant presented a deletion of 273 nucleotides
(D38-310); mutant DNBR-Low2 showed an insertion of a C at
position 147; and mutant DNBR-Low3 had a substitution of C into
T at position 181 leading to a replacement of codon for Gln61 by
a Stop codon. In all cases, mutations resulted in truncated forms of
the repressor protein. Therefore, the overexpression of the
nitroreductase NfnB caused by the altered repressor of the nfnB
gene could account for the resistance to this new class of
antitubercular drugs in DNBR-Low mutants.

Results and Discussion
Isolation and characterization of M. smegmatis resistant
mutants
To better understand the mechanism of resistance to DNBs,
several spontaneous M. smegmatis mutants resistant to DNB3 were
isolated. DNB3 was chosen because of its higher solubility in solid
medium in respect to the other dinitrobenzamide derivatives.
The spontaneous mutants exhibited two different resistance
levels to DNB3. The first series of M. smegmatis DNB resistant
mutants were isolated onto 7H11 containing drug concentrations
ranging from 150 to 300-fold the MIC for the wild-type strain
(0.25 mg/ml) (Table 2) and the second series with concentrations
ranging from 8 to 24-fold the MIC (Table 3).
To confirm the phenotype of these resistant strains, the MIC of
DNB3 was evaluated as described in Materials and Methods.
Moreover, the possible cross-resistance between DNBs and
BTZ043 was checked for all M. smegmatis mutants isolated in this
work and also for three M. smegmatis BTZ043 resistant mutants
isolated in the previous work, GM22, AL49 and AL55 [14]. All
mutants showed cross-resistance to BTZs and DNBs (Tables 2
and 3).
The confirmed MICs for the first series of mutants showed a
high level of resistance to DNB (.800 X MIC) and to BTZ
Table 2. Resistance profile and mutations in M. smegmatis
mutants showing high levels of resistance to DNB.

M. smegmatis
strain

Mutation in
MSMEG_6382

DNB3
MIC (mg/ml)

BTZ-043
MIC (mg/ml)

mc2155

Cys394

0,25

0,004

DNBR-High1

Cys394 R Gly

.200

4

DNBR-High1

Cys394 R Gly

.200

4

DNBR-High2

Cys394 R Gly

.200

4

DNBR-High3

Cys394 R Gly

.200

4

R-High

4

Cys394 R Ser

.200

.16

DNBR-High5

Cys394 R Gly

.200

4

DNBR-High6

Cys394 R Gly

.200

4

DNBR-High7

Cys394 R Gly

.200

4

DNBR-High8

Cys394 R Gly

.200

4

DNBR-High9

Cys394 R Gly

.200

4

DNBR-High10

Cys394 R Gly

.200

4

DNBR-High11

Cys394 R Gly

.200

4

DNBR-High12

Cys394 R Gly

.200

4

13

Cys394 R Gly

.200

4

DNBR-High14

Cys394 R Gly

.200

4

Cys394 R Gly

.200

4

DNB

R-High

DNB

R-High

DNB

15

DNB - DprE1 interaction
DprE1 has been reported to have a FAD binding domain [10],
and effectively the recombinant protein showed the typical
fluorescence emission spectra of the flavin adenine dinucleotide

doi:10.1371/journal.pone.0026675.t002
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Table 3. Resistance profile and mutations in M. smegmatis mutants showing lower levels of resistance to DNB.

M. smegmatis strain

Mutation in MSMEG_6503

DNB3 MIC (mg/ml)

BTZ-043 MIC (mg/ml)

mc 155

-

0.25

0.004

GM22(11)

Leu 137 R Pro

64

0.128

AL49(11)

DAla 15, 16, 17

64

0.128

AL55(11)

Mutation in the repressor binding site

64

0.256

DNBR-Low1

DAla 18 – Ala 108

32

0.064

DNBR-Low2

Thr51Aspfs*46

16

0.064

DNBR-Low3

Gln 61 R Stop

32

0.064

2

doi:10.1371/journal.pone.0026675.t003

levels of nfnB overexpression detected in DNBR-Low1-3 mutants
were higher than those of GM22, AL49 and AL55 mutants
[14].
Therefore, as in the case of BTZ low resistant mutants, the
overexpression of the nitroreductase NfnB turns out to be involved
in the mechanism of resistance of DNBR-Low mutants.
To assess if the overexpressed NfnB was responsible for DNB
inactivation, the purified enzyme was evaluated for its ability to
convert the nitro-form of DNB1 into the corresponding hydroxyl
amine- and/or amino-derivatives. The experiments carried out by
LC/MS2 analysis were performed both in the presence and in the
absence of NADPH, as described in Materials and Methods.
Whereas NfnB was able to convert DNB1 into the corresponding hydroxyl amine-derivative in the presence of NADPH (Figure 2A),
no conversion was observed in the absence of this cofactor
(Figure 2B). On the other hand, no formation of the hydroxyl amineform was observed when NfnB was excluded from the reaction
mixture, thus confirming the role of the enzyme in the drug
transformation (data not shown). However, the DNB aminoderivatives were not detected in our experimental settings. On the
other hand, previous studies performed on M. smegmatis extracts
incubated with DNBs evidenced the production of both amino- and
hydroxyl amine-derivative forms of the drug (data not shown), as in
the case of BTZ compounds [8,14]. Moreover, the in vitro synthesis
of the DNB amino-derivative and hydroxyl amine-form were

(maximal emission at 530 nm with lex = 450 nm) (Figure 1). To
obtain direct evidence on the binding of DNBs to DprE1 the
interactions between the two counterparts were investigated
monitoring the change in fluorescence of the enzyme bound
FAD, in the presence of different ligand concentrations. DNB1
and DNB3 were used for titrations, and in both cases the intensity
of the fluorescence was enhanced by the ligand (Figure 1, A and
B), showing a saturation curve (Figure 1C). Moreover, no
alterations in fluorescence was found when dimethyl sulfoxide,
the solvent of DNBs (see Materials and Methods), was used alone.
The titration curves obtained were fitted to equation 1 (Figure 1C),
and the Kd values determined (7.360.8 mM and 1.860.1 mM for
DNB1 and DNB3, respectively) showed that DprE1 binds both
DNB compounds with high affinity.
This result shows unambiguously that DprE1 is a target of DNB
compounds.

NfnB is responsible for DNB transformation
To verify whether DNB3 resistance in M. smegmatis DNBR-Low
1-3 mutants was really associated to the overexpression of nfnB,
quantitative Real Time PCR (qRT-PCR) experiments were
performed on wild-type M. smegmatis and mutant strains in the
absence of the drug. A statistically significant increase in
transcription of nfnB was observed in DNBR-Low1-3 mutants
with respect to the wild-type strain (Table 4). Moreover, the

Figure 1. Titration of DprE1 with DNBs. Fluorescence spectra of DprE1 at increasing concentrations of DNB1 (A) and DNB3 (B); the fluorescence
intensities are reported in arbitrary units. The dashed lines represent the fluorescence spectra of a blank sample containing 256 mM of ligand. All
measurements were performed at 25uC, as reported in ‘‘Materials and Methods’’ section. (C) Titration curves of DprE1 with DNB1 ( ), and with DNB3
(#). Lines are the fit of the data to equation 1.
doi:10.1371/journal.pone.0026675.g001
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The cellular target of DNB drugs in M. smegmatis is DprE1, wich
is a component of the decaprenylphosphoryl-b-D-ribose 29epimerase, an enzyme involved in arabinogalactan and lipoarabinomannan synthesis in the mycobacterial cell wall. To
accomplish their activity these compounds require the presence
of a cysteine at position 394 of the M. smegmatis DprE1 enzyme.
Substitution of this cysteine by glycine or serine in DprE1 affects
the power binding of DNBs, thus making mycobacteria highly
resistant to these drugs (DNBR-High). Moreover, direct evidence of
interaction between DprE1 and DNBs was demonstrated by
steady state fluorescence titration.
However, the resistance mechanisms can be developed
indirectly, making the DNB molecules less effective through the
reduction of their nitro-forms to hydroxyl amine- and/or aminoderivative. The resulting resistance is achieved through the
overexpression of the gene encoding the nitroreductase NfnB, as
a consequence of its mutated repressor. This last point was also
demonstrated by LC/MS2 where NfnB transformed the nitro form
of DNB into the hydroxyl amine inactive derivative.
Both groups of mutants (DNBR-High and DNBR-Low) display a
behavior towards DNBs similar to that exhibited to BTZs,
indicating that the mechanism of action of DNBs parallels that
suggested for BTZs.
Furthermore, this study presents some novelties: 1. DprE1 is a
target of DNB compounds in M. smegmatis and, consequently, in all
mycobacteria; 2. DprE1 binds the DNBs with high affinity; 3. in
M. smegmatis NfnB is responsible also for DNB inactivation.The
knowledge of the mechanisms of action and of resistance to BTZ
and to DNB will help the design of derivatives less susceptible to
nitroreduction and with a higher in vivo efficacy.

Table 4. nfnB expression levels obtained by Real Time PCR in
different M. smegmatis strains.

M. smegmatis strain

nfnB

mc2155

1

DNBR-Low1

39076307

R-Low

DNB

2

27556271

DNBR-Low3

16026209

doi:10.1371/journal.pone.0026675.t004

successful [15] and these forms of DNB were not effective against
mycobacteria similarly to BTZ derivatives [8,14,15].
In conclusion, the data reported here elucidate the mechanisms
of resistance of DNBs and BTZs in M. smegmatis. Accordingly, we
have demonstrated that DNBs and BTZs have the same target and
the same mechanisms of resistance, hinging on either the mutation
of the target or the transformation of the original nitro compound
into a less active amino or hydroxyl amine derivative.
In this work we only used M. smegmatis for our experiments for
the following reasons:
1. The mechanism of resistance related to NfnB (drug inactivation) is present only in M. smegmatis. Until now in M. tuberculosis
a nitroreductase able to inactivate the BTZ has not been found
[14]. Moreover, the overexpression of nfnB in M. tuberculosis
confers resistance to BTZ [14].
2. In our laboratory we tried to obtain soluble M. tuberculosis
DprE1 soluble protein without success, but we obtained small
amounts of M. smegmatis soluble protein that we used for the
experiment of binding between DprE1 and DNB.
3. M. smegmatis, M. tuberculosis, and M. bovis BCG mutants resistant
to BTZ have the same mutation in the same codon of DprE1.
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Figure 2. LC/MS2 analysis of DNB transformed by NfnB. DNB1 was incubated with M. smegmatis NfnB in presence of NADH and the mixture
was analyzed by LC/MS2 A. DNB1; B. hydroxyl-amine form of DNB1 that is detected after a 30 min incubation at 37uC.
doi:10.1371/journal.pone.0026675.g002
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